Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Summary: Nonbiologic and Biologic DMARDs Compared With Conventional Anti-inflammatoryTreatments (1 of 2)
Improved ESR is inconsistently associated with treatment, and the evidence is insufficient to estimate treatment effects. ESR is influenced by many factors that may be unrelated to treatment.
The evidence about how both biologic and nonbiologic DMARDs affect radiographic evidence of disease progression is insufficient to permit a conclusion about treatment effects.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD | methotrexate | disease activity | health status | erythrocyte sedimentation rate | ESR | radiographic
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.